Corient Private Wealth LLC Sells 2,041 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Corient Private Wealth LLC cut its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 9.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,689 shares of the biotechnology company's stock after selling 2,041 shares during the period. Corient Private Wealth LLC's holdings in United Therapeutics were worth $6,591,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Envestnet Portfolio Solutions Inc. lifted its position in United Therapeutics by 8.1% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,082 shares of the biotechnology company's stock valued at $382,000 after acquiring an additional 81 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in shares of United Therapeutics by 3.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 8,526 shares of the biotechnology company's stock worth $3,008,000 after buying an additional 301 shares during the period. Erste Asset Management GmbH grew its holdings in shares of United Therapeutics by 4.1% during the fourth quarter. Erste Asset Management GmbH now owns 47,136 shares of the biotechnology company's stock worth $16,957,000 after buying an additional 1,870 shares in the last quarter. Achmea Investment Management B.V. raised its position in United Therapeutics by 52.4% in the 4th quarter. Achmea Investment Management B.V. now owns 36,746 shares of the biotechnology company's stock valued at $12,965,000 after buying an additional 12,627 shares during the last quarter. Finally, Vestcor Inc lifted its stake in United Therapeutics by 40.7% in the 4th quarter. Vestcor Inc now owns 1,413 shares of the biotechnology company's stock valued at $499,000 after acquiring an additional 409 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at United Therapeutics

In related news, Director Nilda Mesa sold 255 shares of the business's stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares in the company, valued at $1,966,696.56. The trade was a 4.41 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Monday, December 30th. The shares were sold at an average price of $356.68, for a total transaction of $3,566,800.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $919,164.36. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 80,255 shares of company stock worth $28,995,021 over the last ninety days. Insiders own 11.90% of the company's stock.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of research reports. HC Wainwright reissued a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. Finally, UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $388.25.

United Therapeutics Stock Performance

Shares of United Therapeutics stock traded down $3.13 during midday trading on Tuesday, hitting $316.73. 345,532 shares of the company traded hands, compared to its average volume of 460,156. The stock has a market cap of $14.22 billion, a price-to-earnings ratio of 13.91, a PEG ratio of 0.97 and a beta of 0.64. The firm's fifty day moving average price is $344.24 and its 200-day moving average price is $356.84. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the prior year, the business posted $4.36 earnings per share. Equities research analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.